Alirocumab and Dyslipidemia: Heralding a New Therapeutic Era

Journal Title: Journal of Medical Science And clinical Research - Year 2018, Vol 6, Issue 1

Abstract

Prevention of cardiovascular diseases (CVDs) has been an insurmountable challenge for a clinician. The prevalence of CVDs has been consistently increasing. There is indisputable evidence that Low Density Lipoprotein cholesterol (LDLc) is a principal driver of ASCVD thus LDLc reduction is important to reduce risk of CVDs. LDLc reduction is critically related to improved plaque stability and reduction of atheroma volume. Low Density Lipoprotein cholesterol (LDLc), the primary driver of atherosclerosisis, is the key target for intervention for prevention of CVDs. Yet, despite best treatment by statins which are the first line drugs for the treatment of dyslipidemia, inadequate LDLc reduction can be problematic in high risk patients. PCSK9 antibody, alirocumab was approved by Food and Drug Administration (FDA) in 2015. The addition of alirocumab to statin or any other lipid lowering drug results in clinically significant as well as sustained LDLc reduction with fewer side effects in patients with suboptimal LDLc lowering. Thus, Based on its novel mechanism of action, aliorcumab can be very instrumental for filling the lacuna in the treatment of dyslipidemia.

Authors and Affiliations

Dr Ajay Shukla

Keywords

Related Articles

An Evaluation of the Metabolic Parameters in Women with Gestational Diabetes Mellitus after Delivery

Objective: To evaluate the metabolic parameters in women with gestational diabetes mellitus after delivery in north Indian women. Methods: This was a comparative study. A total of 50 patients were included in the study....

Effect of Health Education Intervention on Knowledge and Practice about reproductive health among Adolescent Female Students

Adolescence is the most important period of one’s Life. It is a fundamental component of an individual's overall health status and a central determinant of quality of life. Aims of the study: The aim of this study was to...

Full Mouth Rehabilitation Involving Occlusal Plane Correction-Case Report

Full mouth rehabilitation is a complex dental treatment the complexity of which relates to mathematical components of occlusion that involves various angulations and inclinations. One of such component is the occlusal pl...

Primary Gastrointestinal Stromal Tumor of Mesentery

Gastrointestinal Stromal tumors (GISTs) are mesenchymal tumors accounting for < 1% of the primary gastrointestinal tumors. Primary GIST of mesentery is extremely rare. We report a case of primary GIST arising from the me...

Etiological Factors Associated in Fever with Thrombocytopenia: A Clinical Study

Objective: This study was conducted to investigate factors associated in fever with thrombocytopenia Patients and Methods: The present observational study was done on 200 patients attending Medicine department, Medical C...

Download PDF file
  • EP ID EP500590
  • DOI -
  • Views 57
  • Downloads 0

How To Cite

Dr Ajay Shukla (2018). Alirocumab and Dyslipidemia: Heralding a New Therapeutic Era. Journal of Medical Science And clinical Research, 6(1), 32713-32722. https://europub.co.uk/articles/-A-500590